Inactive Instrument

Pressure BioSciences, Inc. Stock price Other OTC

Equities

PBIO

US74112E2081

Medical Equipment, Supplies & Distribution

Sales 2021 2M Sales 2022 1.73M Capitalization 15.89M
Net income 2021 -20M Net income 2022 -16M EV / Sales 2021 16.4 x
Net Debt 2021 14.51M Net Debt 2022 20.53M EV / Sales 2022 21.1 x
P/E ratio 2021
-0.68 x
P/E ratio 2022
-0.81 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 98.94%
More Fundamentals * Assessed data
Dynamic Chart
Pressure BioSciences, Inc. Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing CI
Transcript : CBH International LLC, Pressure BioSciences, Inc. - M&A Call
Pressure BioSciences, Inc. completed the acquisition of CBH International LLC. CI
Pressure BioSciences, Inc. Receives Open Order Agreement from West Coast Manufacturing Partner CI
Pressure BioSciences, Inc. entered into a definitive agreement to acquire CBH International LLC. CI
Pressure BioSciences' BaroFold Platform Expected to Revolutionize Biopharmaceutical Production with Help from New Computational (AI/ML) Technologies CI
Pressure BioSciences, Inc. Announces the Publication of Pivotal Scientific Study in the Critical Field of Food Safety CI
Pressure BioSciences and Veterans Service Team Launch UltraShear Best-in-Class Nano-CBD Topical Spray - MMA Champ Cat Zingano Now Official VST Ambassador CI
Transcript : Pressure BioSciences, Inc., Q3 2023 Earnings Call, Nov 21, 2023
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Reports Q3 Revenue $413,009 MT
Pressure BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pressure Biosciences Announces Exclusive Distribution Agreement with Bioscreen Instruments Pvt Ltd CI
Pressure BioSciences' Partner Veterans Service Team Increases Existing Purchase Order by 10X for Bottles of UltraShear Nano-CBD Topical Spray, Effective Immediately CI
Transcript : Pressure BioSciences, Inc., Q2 2023 Earnings Call, Aug 22, 2023
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Posts Q2 Revenue $511,800 MT
More news

Latest transcript on Pressure BioSciences, Inc.

Managers TitleAgeSince
Chief Executive Officer 73 78-07-31
Chief Tech/Sci/R&D Officer 70 06-04-23
Chief Tech/Sci/R&D Officer 59 06-04-02
Members of the board TitleAgeSince
Chief Executive Officer 73 78-07-31
Director/Board Member 75 12-07-02
Director/Board Member 71 13-02-07
More insiders
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions and related consumables for life sciences agriculture, food and beverage, and other industries. The Company's solutions are based on the properties of both constant and alternating, pressure cycling technology (PCT) hydrostatic pressure. Its PCT is an enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to reproducibly control bio-molecular interactions. Its primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Its products include Barocyclers, Barocycler Accessories, External Pressure Calibration Device Kit, MicroTubes for Barocyclers, BaroShear K45, HUB High Pressure Generators and Accessories, HP Cell From ISS, and RF1700 Mini Ultra-High Pressure Pump.
More about the company
  1. Stock
  2. Equities
  3. Stock Pressure BioSciences, Inc.
  4. Stock Pressure BioSciences, Inc. - Other OTC